TNFRSF4 and sarcoma: High transcript levels of 4–1BB and OX40 in UPS, MFS, and DDLS, indicate that these sarcoma subtypes are likely to be a promising cohort of patients for future immunotherapy agents targeting these pathways.27 With emerging data on pembrolizumab from the SARC028 trial, this is likely to be in combination with anti-PD-1 axis blockade.